158 related articles for article (PubMed ID: 22093240)
1. Multiple signal pathways in obesity-associated cancer.
Chen J
Obes Rev; 2011 Dec; 12(12):1063-70. PubMed ID: 22093240
[TBL] [Abstract][Full Text] [Related]
2. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
3. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
4. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
5. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.
Fang P; Hwa V; Rosenfeld RG
Exp Cell Res; 2006 May; 312(8):1229-39. PubMed ID: 16427044
[TBL] [Abstract][Full Text] [Related]
7. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
8. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
9. Role of the mTOR pathway in normal and tumoral adrenal cells.
De Martino MC; van Koetsveld PM; Pivonello R; Hofland LJ
Neuroendocrinology; 2010; 92 Suppl 1():28-34. PubMed ID: 20829615
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
11. Obesity, the PI3K/Akt signal pathway and colon cancer.
Huang XF; Chen JZ
Obes Rev; 2009 Nov; 10(6):610-6. PubMed ID: 19527447
[TBL] [Abstract][Full Text] [Related]
12. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
14. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway.
Chenal J; Pellerin L
J Neurochem; 2007 Jul; 102(2):389-97. PubMed ID: 17394554
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor for the treatment of hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.
Jhanwar-Uniyal M; Albert L; McKenna E; Karsy M; Rajdev P; Braun A; Murali R
Adv Enzyme Regul; 2011; 51(1):164-70. PubMed ID: 21035497
[TBL] [Abstract][Full Text] [Related]
17. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
18. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis.
Chen J; Crawford R; Xiao Y
J Cell Biochem; 2013 Feb; 114(2):245-9. PubMed ID: 22930581
[TBL] [Abstract][Full Text] [Related]
19. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ; Wierusz-Wysocka B
Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]